Tags

Type your tag names separated by a space and hit enter

Rheumotologitsts' view on the use of hydroxychloroquine to treat COVID-19.
Emerg Microbes Infect. 2020 Dec; 9(1):830-832.EM

Abstract

The current pandemic coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls urgently for effective therapies. Anti-malarial medicine chloroquine (CQ) and particularly its chemical analogue hydroxychloroquine (HCQ) have been recommended as promising candidate therapeutics that are now under either compassionate off-label use or clinical trials for the treatment of COVID-19 patients. However, there are public concerns and disputes about both the safety and efficacy of CQ and HCQ for this new application. Given the fact that for decades HCQ has been approved as an immunomodulatory drug for the long term treatment of chronic rheumatic diseases, as experienced rheumatologists, we would like to share our thoughts in this regard and trigger a brainstorm among clinical care providers for exchanging their diverse opinions on this urgent topic.

Authors+Show Affiliations

Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China.Department of Imaging & Pathology, Faculty of Medicine, KU Leuven, Belgium.Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China.

Pub Type(s)

Letter

Language

eng

PubMed ID

32338155

Citation

Sun, Xiaoxuan, et al. "Rheumotologitsts' View On the Use of Hydroxychloroquine to Treat COVID-19." Emerging Microbes & Infections, vol. 9, no. 1, 2020, pp. 830-832.
Sun X, Ni Y, Zhang M. Rheumotologitsts' view on the use of hydroxychloroquine to treat COVID-19. Emerg Microbes Infect. 2020;9(1):830-832.
Sun, X., Ni, Y., & Zhang, M. (2020). Rheumotologitsts' view on the use of hydroxychloroquine to treat COVID-19. Emerging Microbes & Infections, 9(1), 830-832. https://doi.org/10.1080/22221751.2020.1760145
Sun X, Ni Y, Zhang M. Rheumotologitsts' View On the Use of Hydroxychloroquine to Treat COVID-19. Emerg Microbes Infect. 2020;9(1):830-832. PubMed PMID: 32338155.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rheumotologitsts' view on the use of hydroxychloroquine to treat COVID-19. AU - Sun,Xiaoxuan, AU - Ni,Yicheng, AU - Zhang,Miaojia, PY - 2020/4/28/pubmed PY - 2020/5/6/medline PY - 2020/4/28/entrez KW - COVID-19 KW - Chloroquine (CQ) KW - SARS-CoV-2 KW - hydroxychloroquine (HCQ) KW - therapy SP - 830 EP - 832 JF - Emerging microbes & infections JO - Emerg Microbes Infect VL - 9 IS - 1 N2 - The current pandemic coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls urgently for effective therapies. Anti-malarial medicine chloroquine (CQ) and particularly its chemical analogue hydroxychloroquine (HCQ) have been recommended as promising candidate therapeutics that are now under either compassionate off-label use or clinical trials for the treatment of COVID-19 patients. However, there are public concerns and disputes about both the safety and efficacy of CQ and HCQ for this new application. Given the fact that for decades HCQ has been approved as an immunomodulatory drug for the long term treatment of chronic rheumatic diseases, as experienced rheumatologists, we would like to share our thoughts in this regard and trigger a brainstorm among clinical care providers for exchanging their diverse opinions on this urgent topic. SN - 2222-1751 UR - https://www.unboundmedicine.com/medline/citation/32338155/Rheumotologitsts'_view_on_the_use_of_hydroxychloroquine_to_treat_COVID_19_ L2 - https://www.tandfonline.com/doi/full/10.1080/22221751.2020.1760145 DB - PRIME DP - Unbound Medicine ER -